Test Id : ACRN
Acylcarnitines, Quantitative, Plasma
Useful For
Suggests clinical disorders or settings where the test may be helpful
Diagnosis of fatty acid oxidation disorders and several organic acidurias using plasma specimens
Evaluating treatment during follow-up of patients with fatty acid beta-oxidation disorders and several organic acidurias
Method Name
A short description of the method used to perform the test
Flow Injection Analysis-Tandem Mass Spectrometry (FIA-MS/MS)
NY State Available
Indicates the status of NY State approval and if the test is orderable for NY State clients.
Reporting Name
Lists a shorter or abbreviated version of the Published Name for a test
Aliases
Lists additional common names for a test, as an aid in searching
2-Methylbutyryl-CoA Dehydrogenase Deficiency
3-Methylcrotonyl Carboxylase Deficiency
Biotinidase (Multiple Carboxylase) Deficiency
CPT-II (Carnitine Palmitoyl Transferase Deficiency Type II)
Electron-Transfer Flavoprotein (ETF) Deficiency
Glutaric Acidemia (GA)
Glutaric Acidemia Type I (GA I)
Glutaric Acidemia Type II (GA II)
Glutaryl-CoA Dehydrogenase (GCDH) Deficiency
Isobutyryl-CoA Dehdrogenase (IBDH) Deficiency
Isovaleric Acidemia (IVA)
Long-Chain 3-Hydroxyacyl-CoA Dehydrogenase (LCHAD) Deficiency
MADD (Multiple Acyl-CoA Dehydrogenase Deficiency)
Malonic aciduria
Medium-Chain Acyl-CoA Dehydrogenase (MCAD) Deficiency
Methylmalonic Acidemia
Methylmalonic Aciduria (MMA)
Multiple Acyl-CoA Dehydrogenase Deficiency (MADD)
S/MCHAD (Short/Medium-Chain 3-Hydroxyacyl-CoA Dehydrogenase) Deficiency
SCAD (Short-Chain Acyl-CoA Dehydrogenase) Deficiency
Short/Medium-Chain 3-Hydroxyacyl-CoA Dehydrogenase (S/MCHAD) Deficiency
Trifunctional Protein (TFP) Deficiency
Very Long-Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency
2-Methyl-3-hydroxybutyryl CoA Dehydrogenase Deficiency
3-Hydroxy-3-Methylglutaryl-CoA (HMG-CoA) Lyase Deficiency
3-Methylglutaconyl-CoA Hydratase Deficiency
Beta-ketothiolase Deficiency
Carnitine-acylcarnitine Translocase (CACT) Deficiency
Formiminoglutamic Aciduria (FIGLU)
Formiminotransferase (FIGLU) Deficiency
Holocarboxylase Synthetase Deficiency
Succinyl-CoA Ligase (SUCLA2) Deficiency
SUCLA2 (Succinyl-CoA Ligase) Deficiency
3-Methylglutaconic Aciduria Type I
3-Methylglutaconic Aciduria Type 1
Propionic Acidemia (PA)
Specimen Type
Describes the specimen type validated for testing
Plasma
Necessary Information
1. Patient's age is required.
2. Include family history, clinical condition (asymptomatic or acute episode), diet, and drug therapy information.
Specimen Required
Defines the optimal specimen required to perform the test and the preferred volume to complete testing
Patient Preparation: Collect specimen just prior to a scheduled meal or feeding.
Collection Container/Tube:
Preferred: Green top (sodium heparin)
Acceptable: Lavender top (EDTA) or green top (lithium heparin)
Submission Container/Tube: Plastic vial
Specimen Volume: 0.1 mL
Collection Instructions: Centrifuge and aliquot plasma into plastic vial.
Forms
If not ordering electronically, complete, print, and send a Biochemical Genetics Test Request (T798) with the specimen.
Specimen Minimum Volume
Defines the amount of sample necessary to provide a clinically relevant result as determined by the testing laboratory. The minimum volume is sufficient for one attempt at testing.
0.04 mL
Reject Due To
Identifies specimen types and conditions that may cause the specimen to be rejected
| Gross hemolysis | OK |
| Gross lipemia | OK |
| Gross icterus | OK |
Specimen Stability Information
Provides a description of the temperatures required to transport a specimen to the performing laboratory, alternate acceptable temperatures are also included
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Plasma | Frozen (preferred) | 92 days | |
| Ambient | 8 days | ||
| Refrigerated | 64 days |
Useful For
Suggests clinical disorders or settings where the test may be helpful
Diagnosis of fatty acid oxidation disorders and several organic acidurias using plasma specimens
Evaluating treatment during follow-up of patients with fatty acid beta-oxidation disorders and several organic acidurias
Clinical Information
Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test
Acylcarnitine analysis enables the diagnosis of many disorders of fatty acid oxidation and several organic acidurias, as relevant enzyme deficiencies cause the accumulation of specific acyl-CoAs.(1) Fatty acid oxidation (FAO) plays a major role in energy production during periods of fasting. When the body's supply of glucose is depleted, fatty acids are mobilized from adipose tissue, taken up by the liver and muscles, and oxidized to acetyl-CoA. In the liver, acetyl-CoA is the building block for the synthesis of ketone bodies, which enter the blood stream and provide an alternative substrate for production of energy in other tissues when the supply of glucose is insufficient to maintain a normal level of energy. The acyl groups are conjugated with carnitine to form acylcarnitines, which can be measured by tandem mass spectrometry. Diagnostic results are usually characterized by a pattern of significantly elevated acylcarnitine species compared to normal and disease controls.
In general, more than 20 inborn errors of metabolism can be identified using this method, including FAO disorders and organic acidurias. The major clinical manifestations associated with individual FAO disorders include hypoketotic hypoglycemia, variable degrees of liver disease and failure, skeletal myopathy, dilated/hypertrophic cardiomyopathy, and sudden or unexpected death. Organic acidurias also present as acute life-threatening events early in life with metabolic acidosis, increased anion gap, and neurologic distress. Patients with any of these disorders are at risk of developing fatal metabolic decompensations following the acquisition of even common infections. Once diagnosed, these disorders can be treated by avoidance of fasting, special diets, and cofactor and vitamin supplementation.
Additional confirmatory testing is recommended. The diagnosis of an underlying FAO disorder or organic aciduria allows genetic counseling of the family, including the possible option of future prenatal diagnosis, and testing of at-risk family members of any age.
The following disorders are detectable by acylcarnitine analysis. However, further confirmatory testing is required for most of these conditions because an acylcarnitine profile can be suggestive of more than one condition.
Fatty Acid Oxidation Disorders:
-Carnitine palmitoyltransferase I deficiency
-Medium-chain 3-ketoacyl-CoA thiolase deficiency
-Dienoyl-CoA reductase deficiency
-Short-chain acyl-CoA dehydrogenase deficiency
-Medium/Short-chain 3-hydroxyacyl-CoA dehydrogenase deficiency
-Medium-chain acyl-CoA dehydrogenase deficiency
-Long-chain 3-hydroxyacyl-CoA dehydrogenase) deficiency and trifunctional protein deficiency
-Very long-chain acyl-CoA dehydrogenase deficiency
-Carnitine palmitoyl transferase type II deficiency
-Carnitine-acylcarnitine translocase deficiency
-Electron transfer flavoprotein (ETF) deficiency, ETF-dehydrogenase deficiency (multiple acyl-CoA dehydrogenase deficiency; glutaric acidemia type II)
Organic Acid Disorders:
-Glutaryl-CoA dehydrogenase deficiency (glutaric acidemia type I)
-Propionic acidemia
-Methylmalonic acidemia
-Isovaleric acidemia
-3-Hydroxy-3-methylglutaryl-CoA carboxylase deficiency
-3-Methylcrotonyl carboxylase deficiency
-Biotinidase deficiency
-Multiple carboxylase deficiency
-Isobutyryl-CoA dehydrogenase deficiency
-2-Methylbutyryl-CoA dehydrogenase deficiency
-Beta-ketothiolase deficiency
-Malonic aciduria
-Ethylmalonic encephalopathy
-Glutamate formiminotransferase deficiency (formiminoglutamic aciduria)
Reference Values
Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.
| < or =7 days (nmol/mL) | 8 days-7 years (nmol/mL) | > or =8 years (nmol/mL) | |
| Acetylcarnitine, C2 | 2.14-15.89 | 2.00-27.57 | 2.00-17.83 |
| Acrylylcarnitine, C3:1 | <0.04 | <0.05 | <0.07 |
| Propionylcarnitine, C3 | <0.55 | <1.78 | <0.88 |
| Formiminoglutamate, FIGLU | <0.43 | <0.08 | <0.14 |
| Iso-/Butyrylcarnitine, C4 | <0.46 | <1.06 | <0.83 |
| Tiglylcarnitine, C5:1 | <0.05 | <0.09 | <0.11 |
| Isovaleryl-/2-Methylbutyrylcarn C5 | <0.38 | <0.63 | <0.51 |
| 3-OH-iso-/butyrylcarnitine, C4-OH | <0.13 | <0.51 | <0.18 |
| Hexenoylcarnitine, C6:1 | <0.12 | <0.10 | <0.15 |
| Hexanoylcarnitine, C6 | <0.14 | <0.23 | <0.17 |
| 3-OH-isovalerylcarnitine, C5-OH | <0.08 | <0.12 | <0.10 |
| Benzoylcarnitine | <0.13 | <0.07 | <0.10 |
| Heptanoylcarnitine, C7 | <0.05 | <0.05 | <0.06 |
| 3-OH-hexanoylcarnitine, C6-OH | <0.08 | <0.19 | <0.09 |
| Phenylacetylcarnitine | <0.15 | <0.22 | <0.29 |
| Salicylcarnitine | <0.08 | <0.09 | <0.09 |
| Octenoylcarnitine, C8:1 | <0.48 | <0.91 | <0.88 |
| Octanoylcarnitine, C8 | <0.19 | <0.45 | <0.78 |
| Malonylcarnitine, C3-DC | <0.09 | <0.14 | <0.26 |
| Decadienoylcarnitine, C10:2 | <0.11 | <0.12 | <0.26 |
| Decenoylcarnitine, C10:1 | <0.25 | <0.46 | <0.47 |
| Decanoylcarnitine, C10 | <0.27 | <0.91 | <0.88 |
| Methylmalonyl-/succinylcarn, C4-DC | <0.05 | <0.05 | <0.05 |
| 3-OH-decenoylcarnitine, C10:1-OH | <0.12 | <0.12 | <0.13 |
| Glutarylcarnitine, C5-DC | <0.06 | <0.10 | <0.11 |
| Dodecenoylcarnitine, C12:1 | <0.19 | <0.37 | <0.35 |
| Dodecanoylcarnitine, C12 | <0.18 | <0.35 | <0.26 |
| 3-Methylglutarylcarnitine, C6-DC | <0.28 | <0.21 | <0.43 |
| 3-OH-dodecenoylcarnitine, C12:1-OH | <0.11 | <0.10 | <0.13 |
| 3-OH-dodecanoylcarnitine, C12-OH | <0.06 | <0.09 | <0.08 |
| Tetradecadienoylcarnitine, C14:2 | <0.09 | <0.13 | <0.18 |
| Tetradecenoylcarnitine, C14:1 | <0.16 | <0.35 | <0.24 |
| Tetradecanoylcarnitine, C14 | <0.11 | <0.15 | <0.12 |
| Octanedioylcarnitine, C8-DC | <0.25 | <0.19 | <0.19 |
| 3-OH-tetradecenoylcarnitine C14:1OH | <0.06 | <0.18 | <0.13 |
| 3-OH-tetradecanoylcarnitine, C14-OH | <0.04 | <0.05 | <0.08 |
| Hexadecenoylcarnitine, C16:1 | <0.15 | <0.21 | <0.10 |
| Hexadecanoylcarnitine, C16 | <0.36 | <0.52 | <0.23 |
| 3-OH-hexadecenoylcarnitine,C16:1-OH | <0.78 | <0.36 | <0.06 |
| 3-OH-hexadecanoylcarnitine, C16-OH | <0.10 | <0.07 | <0.06 |
| Octadecadienoylcarnitine, C18:2 | <0.12 | <0.31 | <0.24 |
| Octadecenoylcarnitine, C18:1 | <0.25 | <0.45 | <0.39 |
| Octadecanoylcarnitine, C18 | <0.10 | <0.12 | <0.14 |
| Dodecanedioylcarnitine, C12-DC | <0.10 | <0.04 | <0.04 |
| 3-OH-octadecadienoylcarn, C18:2-OH | <0.04 | <0.06 | <0.06 |
| 3-OH-octadecenoylcarnitine C18:1-OH | <0.03 | <0.04 | <0.06 |
| 3-OH-octadecanoylcarnitine, C18-OH | <0.03 | <0.05 | <0.03 |
Interpretation
Provides information to assist in interpretation of the test results
An interpretive report is provided. The individual quantitative results support the interpretation of the acylcarnitine profile but are not diagnostic by themselves. The interpretation is based on pattern recognition.
Abnormal results are typically not sufficient to conclusively establish a diagnosis of a particular disease. To verify a preliminary diagnosis based on an acylcarnitine analysis, independent biochemical or molecular genetic analyses are required.
Cautions
Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances
In a few instances, false-negative results occur in the analysis of acylcarnitine profiles. For some disorders, such as medium-chain acyl-CoA dehydrogenase deficiency, the calculation of ratios between different acylcarnitine species provides a discriminate factor to overcome such problems. Where applicable, the calculation of such ratios will be incorporated in the routine acylcarnitine analysis. Informative profiles may also not be detected in some disorders where the accumulation of diagnostic acylcarnitines is a reflection of the residual activity of the defective enzyme, the dietary load of precursors, and the anabolic/catabolic and treatment status of a patient.
Patients with carnitine deficiency may not exhibit abnormally high acylcarnitine concentrations. If the results are indicative for carnitine deficiency, the interpretation will include a remark that this limits the diagnostic value of the test and repeat analysis may be considered following carnitine supplementation.
Follow-up testing such as in vitro enzyme assays or molecular genetic testing may be recommended following abnormal acylcarnitine results. It is not advisable to intentionally stress the patient's metabolism (eg, fasting test) prior to specimen collection for acylcarnitine analysis.
Clinical Reference
Recommendations for in-depth reading of a clinical nature
1. Miller MJ, Cusmano-Ozog K, Oglesbee D, Young S; ACMG Laboratory Quality Assurance Committee. Laboratory analysis of acylcarnitines, 2020 update: a technical standard of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2021;23(2):249-258
2. Matern D. Acylcarnitines, including in vitro loading tests. In: Blau N, Duran M, Gibson KM, eds. Laboratory Guide to the Methods in Biochemical Genetics. Springer Verlag; 2008:171-206
3. Rinaldo P, Cowan TM, Matern D. Acylcarnitine profile analysis. Genet Med. 2008;10(2):151-156
4. Smith EH, Matern D. Acylcarnitine analysis by tandem mass spectrometry. Curr Protoc Hum Genet. 2010;Chap 17:Unit 17.8.1-20
5. Elizondo G, Matern D, Vockley J, Harding CO, Gillingham MB. Effects of fasting, feeding and exercise on plasma acylcarnitines among subjects with CPT2D, VLCADD and LCHADD/TFPD. Mol Genet Metab. 2020;131(1-2):90-97
Method Description
Describes how the test is performed and provides a method-specific reference
Six internal standards of known concentration (d3-acetylcarnitine, d3-propionylcarnitine, d7-butyrylcarnitine, d3-octanoylcarnitine, d3-dodecanoylcarnitine, and d3-palmitoyl-carnitine) and acetonitrile for deproteinization are added to plasma. The supernate is dried and then treated with n-butanolic HCl yielding the acylcarnitines, which are analyzed as their n-butylesters by electrospray ionization tandem mass spectrometry. The concentrations of the analytes are established by computerized comparison of these analytes' ion intensities to those of the closest internal standard.(Van Hove JL, Kahler SG, Feezor MD, et al. Acylcarnitines in plasma and blood spots of patients with long-chain 3-hydroxyacylcoenzyme A dehydrogenase deficiency. J Inherit Metab Dis. 2000;23:571-582; Miller MJ, Cusmano-Ozog K, Oglesbee D, Young S; ACMG Laboratory Quality Assurance Committee. Laboratory analysis of acylcarnitines, 2020 update: a technical standard of the American College of Medical Genetics and Genomics [ACMG]. Genet Med. 2021;23[2]:249-258)
PDF Report
Indicates whether the report includes an additional document with charts, images or other enriched information
Day(s) Performed
Outlines the days the test is performed. This field reflects the day that the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time before the test is performed. Some tests are listed as continuously performed, which means that assays are performed multiple times during the day.
Monday through Friday
Report Available
The interval of time (receipt of sample at Mayo Clinic Laboratories to results available) taking into account standard setup days and weekends. The first day is the time that it typically takes for a result to be available. The last day is the time it might take, accounting for any necessary repeated testing.
Specimen Retention Time
Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded
Performing Laboratory Location
Indicates the location of the laboratory that performs the test
Fees :
Several factors determine the fee charged to perform a test. Contact your U.S. or International Regional Manager for information about establishing a fee schedule or to learn more about resources to optimize test selection.
- Authorized users can sign in to Test Prices for detailed fee information.
- Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact Customer Service.
Test Classification
Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR) product.
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.
CPT Code Information
Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Clinic Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.
CPT codes are provided by the performing laboratory.
CPT codes are provided by the performing laboratory.
82017
LOINC® Information
Provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the order and results codes of this test. LOINC values are provided by the performing laboratory.
| Test Id | Test Order Name | Order LOINC Value |
|---|---|---|
| ACRN | Acylcarnitines, Quantitative, P | 43433-2 |
| Result Id | Test Result Name |
Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
|
|---|---|---|
| 82413 | Acylcarnitines, Quantitative, P | 46252-3 |
| 10288 | Acetylcarnitine, C2 | 30191-1 |
| 10289 | Propionylcarnitine, C3 | 30551-6 |
| 10290 | Iso-/Butyrylcarnitine, C4 | 43243-5 |
| 10293 | Isovaleryl-/2-Methylbutyrylcarn C5 | 30531-8 |
| 10295 | Hexanoylcarnitine, C6 | 30358-6 |
| 10297 | 3-OH-hexanoylcarnitine, C6-OH | 30236-4 |
| 10298 | Octenoylcarnitine, C8:1 | 30541-7 |
| 10299 | Octanoylcarnitine, C8 | 30540-9 |
| 10301 | Decenoylcarnitine, C10:1 | 30328-9 |
| 10302 | Decanoylcarnitine, C10 | 30327-1 |
| 10304 | Glutarylcarnitine, C5-DC | 30349-5 |
| 10305 | Dodecenoylcarnitine, C12:1 | 30332-1 |
| 10306 | Dodecanoylcarnitine, C12 | 30331-3 |
| 10307 | 3-OH-dodecanoylcarnitine, C12-OH | 30233-1 |
| 10308 | Tetradecadienoylcarnitine, C14:2 | 30564-9 |
| 10309 | Tetradecenoylcarnitine, C14:1 | 30566-4 |
| 10310 | Tetradecanoylcarnitine, C14 | 30565-6 |
| 10311 | 3-OH-tetradecenoylcarnitine C14:1OH | 30190-3 |
| 10312 | 3-OH-tetradecanoylcarnitine, C14-OH | 30238-0 |
| 10313 | Hexadecenoylcarnitine, C16:1 | 30357-8 |
| 10314 | Hexadecanoylcarnitine, C16 | 30356-0 |
| 10315 | 3-OH-hexadecenoylcarnitine,C16:1-OH | 30235-6 |
| 10316 | 3-OH-hexadecanoylcarnitine, C16-OH | 30234-9 |
| 10317 | Octadecadienoylcarnitine, C18:2 | 30534-2 |
| 10318 | Octadecenoylcarnitine, C18:1 | 30542-5 |
| 10319 | Octadecanoylcarnitine, C18 | 30560-7 |
| 10320 | 3-OH-octadecadienoylcarn, C18:2-OH | 30237-2 |
| 10321 | 3-OH-octadecenoylcarnitine C18:1-OH | 30312-3 |
| 10322 | Comment (ACRN) | 48767-8 |
| 36497 | Acrylylcarnitine, C3:1 | 43235-1 |
| 36498 | Formiminoglutamate, FIGLU | 79628-4 |
| 36499 | Tiglylcarnitine, C5:1 | 51416-6 |
| 36500 | 3-OH-iso-/butyrylcarnitine, C4-OH | 39000-5 |
| 36501 | Hexenoylcarnitine, C6:1 | 74540-6 |
| 36502 | 3-OH-isovalerylcarnitine, C5-OH | 39001-3 |
| 36503 | Benzoylcarnitine | 39615-0 |
| 36504 | Heptanoylcarnitine, C7 | 55871-8 |
| 36505 | Phenylacetylcarnitine | 90237-9 |
| 36506 | Salicylcarnitine | 90238-7 |
| 36507 | Malonylcarnitine, C3-DC | 55940-1 |
| 36508 | Decadienoylcarnitine, C10:2 | 53471-9 |
| 36509 | Methylmalonyl-/succinylcarn, C4-DC | 51415-8 |
| 36510 | 3-OH-decenoylcarnitine, C10:1-OH | 82478-9 |
| 36511 | 3-Methylglutarylcarnitine, C6-DC | 39002-1 |
| 36512 | 3-OH-dodecenoylcarnitine, C12:1-OH | 59195-8 |
| 36513 | Octanedioylcarnitine, C8-DC | 39014-6 |
| 36514 | Dodecanedioylcarnitine, C12-DC | 55855-1 |
| 36515 | 3-OH-octadecanoylcarnitine, C18-OH | 35656-8 |